Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. - Wikidata - awgldk - TriplyDB

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

http://www.wikidata.org/entity/Q36746785

about

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.Current phase II clinical data for ridaforolimus in cancer.Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.Fulvestrant for the treatment of endometrial cancer.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.FK506-binding protein 12 ligands: a patent review.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Molecular staging of gynecological cancer: What is the future?ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study Recent Advances in Endometrial Cancer.A Review of mTOR Pathway Inhibitors in Gynecologic Cancer The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Emerging drugs for endometrial cancer.Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?Putative tumor suppression function of SIRT6 in endometrial cancer.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.Endometrial Carcinoma: Specific Targeted Pathways.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.New therapies for advanced, recurrent, and metastatic endometrial cancers.A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

P2860

Q30407709-A4DC843C-B198-48E7-A9FC-34EF4A90CAD0 Q30662689-0F10FB3D-C4D1-401A-9F94-DDEEFA479199 Q33442539-1A0F5525-ABC4-4253-B9B9-C1CA0F3F084F Q34514391-755ABB64-B776-4C0D-A05C-5A68B59167F3 Q34781699-3395A553-3DE1-4B60-8108-5F204C251A8B Q34955459-40FD84BA-B5BF-4443-BC77-B3E6EF82E822 Q35144264-05EB58AD-BFE6-42F6-BF3B-04DF935CE354 Q35940829-07EEC3A8-A00F-4F07-BB28-D441F80E6CA0 Q36372293-0150A002-624B-4FEE-8B90-E2F689BECF87 Q36631823-F02400FE-6FEC-44ED-ADC9-D1E0A84295B6 Q37429034-CADA2838-9D0C-4E8E-A601-A76806EAA418 Q37620470-8594B090-9619-450D-8ECD-4A0908C0A604 Q37668889-1C6A7ABC-5479-4C1F-8DC3-76E8CBE644A7 Q38195885-85B8D556-5E04-42B3-9EB4-3BE405A013D7 Q38203354-9278E8CB-DF0E-422D-A6B6-05F2C1F99136 Q38242086-242B108D-3807-4E47-A161-29DC30AC060A Q38261469-D540516C-EC44-467D-89A9-8B08C87EAFB9 Q38297206-A760E89C-EA96-4571-B3C8-87AD00A632DB Q38378472-CA894F05-E0BE-4324-BF75-B51C41371FF9 Q38515841-66859E89-5CAB-4924-886B-B880E9193157 Q38603164-9D3EE8F6-175F-4863-B800-D219E51E4AA0 Q38631272-A26A7B21-C7C3-4520-A3A4-250E36D4EE15 Q38753038-21EDA2FA-346F-4132-BFD4-B0F3658BB7E3 Q38852078-2A3AEF44-E80C-4FA0-BFB0-8D653985465F Q38895754-C9E2D977-9F4A-42BC-AA6C-0993CDD28CDD Q38912656-97ADC5B4-44A7-45AB-995C-C9ADF5A3F1D7 Q39026766-156F48A1-079E-4C63-ACE0-BEE7B08E2C56 Q45848384-46FD0B0E-5A5B-43AA-A2ED-5225B07AEC5A Q47103210-36C6B2AE-D88E-46ED-A058-038AA64B505E Q47582481-B14410B5-4145-4A0A-9815-84F48BEA0647 Q55005815-32D610D8-DFAA-470D-B1F2-87BCF3BFB42E Q56019470-48AFE945-F59A-42AE-A074-3D20B8961984 Q57903637-D82B9ED9-010D-48D2-9045-9E6C96965772

P2860

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

http://www.wikidata.org/entity/Q36746785

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Ridaforolimus as a single agen ...... f a single-arm, phase 2 trial.

@en

type

label

Ridaforolimus as a single agen ...... f a single-arm, phase 2 trial.

@en

prefLabel

Ridaforolimus as a single agen ...... f a single-arm, phase 2 trial.

@en

P1433

Q36746785-FA101ADA-9EC2-468D-8836-A34967C2E85C

P1476

Q36746785-F0C12283-72D6-4878-A8EC-E3F35FEA2BEF

P2093

Q36746785-020AF5D1-3303-4B73-8947-FD8F89CC547A

Q36746785-1A0401CB-4B5B-4251-8403-A5D4365D61D0

Q36746785-245549BC-1AA9-493B-8BF4-3D0499FB15AC

Q36746785-46778305-CE86-461D-ACE4-594FBB9EAC22

Q36746785-523C4177-54C2-43D8-95AB-498011B8841D

Q36746785-8B65D307-0775-41C3-A090-A3C3F6A2FEB5

Q36746785-A251DCC2-3A5C-4601-B1CE-1272B391355D

Q36746785-A791F364-ACAC-43C2-AFA4-094A6BA21284

Q36746785-D69B8039-CB71-465C-BFB1-929CE0DA5462

Q36746785-D8CE0E96-D2BB-4E39-A813-13622851DDF0

P2860

Q36746785-1186086B-BAD5-4E76-955A-355EA24B7DCA

Q36746785-19E57423-3EF8-46A6-ACEC-D3D52A3BBAD2

Q36746785-19F293E1-2D19-4404-BB2C-3AADBD307B20

Q36746785-2CD9BFD9-A632-49AD-AE3A-C32DB3FF0736

Q36746785-372BFBEE-DA37-4F1B-AFF2-A7A8B4F44D17

Q36746785-40746F90-0507-49E3-AB16-20DB4212C8B1

Q36746785-5C525D77-96E7-48FA-BC96-68336E1B1F95

Q36746785-5E06079F-0104-4A3C-A5AE-28632374D8F3

Q36746785-61BB4710-655A-43EA-AB4C-9AFFED3DCAF9

Q36746785-6BE07646-6CC8-403F-9470-9F86FF491198

P2888

Q36746785-876F9555-C133-4FD6-AC19-14D673BEC6FE

P304

Q36746785-6DCB76A3-3E1C-4456-98A5-B90CBF05BB75

P31

Q36746785-F512409E-D523-49AC-B28E-1884C341678B

P3181

Q36746785-B067FE4C-B959-4C1B-A693-CEABF5FF64F8

P356

Q36746785-256C7F16-0C91-4DFB-86E2-45D79FD3BB55

P407

Q36746785-7FF29623-A7BF-49B1-98B9-28E32DE21CEC

P433

Q36746785-85992165-3864-410A-A3EE-CD27C65C52CB

P478

Q36746785-5C60DDFA-33AA-4509-9786-A2713082E6CA

P50

Q36746785-9C8A184F-5F5F-4FF6-9B53-E169B04D80B3

P577

Q36746785-B1EE0E46-2887-41A6-8D1B-CF9196BD49A2

P5875

Q36746785-C1078155-7C95-4FAD-AAB0-F6E855BBE4C4

P698

Q36746785-C910E3FB-64D0-458E-8E12-E494730C124A

P921

Q36746785-AC7F1244-C453-474E-9FF2-4C3FF00BFDF8

P932

Q36746785-24868212-0986-471C-929B-9F1C6BB23C94

P3181

P356

P1433

British Journal of Cancer

P1476

Ridaforolimus as a single agen ...... of a single-arm, phase 2 trial

@en

P2093

A Morosky

http://www.w3.org/2001/XMLSchema#string

C Sessa

http://www.w3.org/2001/XMLSchema#string

D S McMeekin

http://www.w3.org/2001/XMLSchema#string

F Haluska

http://www.w3.org/2001/XMLSchema#string

M H Einstein

http://www.w3.org/2001/XMLSchema#string

N Colombo

http://www.w3.org/2001/XMLSchema#string

P A Gehrig

http://www.w3.org/2001/XMLSchema#string

P Braly

http://www.w3.org/2001/XMLSchema#string

P E Schwartz

http://www.w3.org/2001/XMLSchema#string

P F Dodion

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.

Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice

Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium.

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

P2888

P304

1021-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

571

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BJC.2013.59

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235604064

http://www.w3.org/2001/XMLSchema#string

P698

23403817

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3619076

http://www.w3.org/2001/XMLSchema#string